March 14th 2024
The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.
November 21st 2022
The Evolving Treatment Landscape of Acid-Related Disorders: The Role of New and Emerging Potassium-Competitive Acid Blocker Therapies (Pharmacist Credit)
Navigating Next-Generation Therapies for the Management of Acid-Related Disorders
Tremelimumab Added to Durvalumab Shows Positive Results in HCC
Prognostic Nutritional Index May Be Associated With Survival in HCC
Children, Adolescents Considered Obese May Have Greater Risk of NAFLD